Biotech IPOs Raised .7 Billion in Q1 2026 — Most Since 2021 Bubble Peak

Slow Pace, Mega Rounds: Biotech IPO Market Evolves in New Era

Biotechnology companies collectively raised .7 billion in initial public offerings during the first quarter of 2026, the most of any quarter since the 2021 biotech bubble, according to BioPharma Dive data.

Key Numbers

• Total raised: .7 billion in Q1 2026
• Companies that priced: 6 (low count, similar to 2022-2025)
• Median deal size: .5 million (more than double last year)
• Three companies raised over million each (rare since 2021)
• Zero preclinical companies have gone public since 2024

What Changed

While the number of offerings remains suppressed, the size of individual deals has exploded. Companies that manage to price are:

• Developing drugs in mid- or late-stage clinical testing
• Previously raised large venture rounds
• Working in hot therapeutic areas like autoimmune conditions and cancer

Why the Slowdown

Two main factors are holding back the IPO market:

1. Macroeconomic uncertainty including the Middle East conflict causing surging volatility
2. Revolving door at the FDA creating regulatory unpredictability

Investor Perspective

Biotech investors were optimistic at the beginning of 2026 that IPOs were poised for a rebound. The data shows the market has not spiked as hoped, but the larger deal sizes suggest that quality companies can still command significant capital.

Source: BioPharma Dive https://www.biopharmadive.com/news/biotech-ipo-performance-q1-2026/815879/